Extra heart recruits for Mesoblast
Friday, 27 February, 2009
A good safety report has allowed recruitment to proceed of a further group of patients for a Phase II trial of Angioblast’s Revascor universal adult stem cell product.
Angioblast, the US-based sister company of Melbourne’s Mesoblast, is conducting a Phase II trial of Revascor in patients with congestive heart failure.
No adverse effects were recorded in the first 20 patients on a low dose of the product. Recruitment will now begin for another 20-person group to receive a higher dose.
The allogeneic stem cell product is being developed to reverse congestive heart failure by rebuilding blood vessels and heart muscle.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
